• Several reports of single cases of MG patients treated

  2023-12-20

  

  Several reports of single cases of MG patients treated with Rituximab have claimed a favourable response (Baek et al., 2007, Gajra et al., 2004, Hain et al., 2006, Thakre et al., 2007, Wylam et al., 2003, Zaja et al., 2000). We report our experience with Rituximab in 6 patients with severe MG, 3 pa

• Finasteride has been shown to

  2023-12-19

  

  Finasteride has been shown to be a mechanism-based inhibitor of 5AR-2 [9]. Finasteride acts as an alternate substrate for 5AR-2 and is initially bound in an extremely stable enzyme-bound NADP-dihydrofinasteride adduct which is ultimately processed to dihydrofinasteride. The NADP-dihydrofinasteride a

• The first rationally designed dual mPGES LO

  2023-12-19

  

  The first rationally designed dual mPGES-1/5-LO inhibitor was reported in 2008 and represents a structural derivative of pirinixic nos abbreviation - a synthetic agonist of PPARα with lipid-lowering properties (Koeberle et al., 2008b). Further α-alkyl- and α-aryl-substituted derivatives have been sy

• HCC aetiology is multifactorial and

  2023-12-19

  

  HCC aetiology is multifactorial and the disease is often preceded by other conditions including liver fibrosis and cirrhosis that are associated with HCV, HBV, alcoholic and non-alcoholic hepatitis. The discovery of new therapeutic targets will require a greater understanding of the pathogenic mecha

• dpn australia Aurora kinases were initially identified as pr

  2023-12-19

  

  Aurora kinases were initially identified as protein kinases essential for error-free chromosome segregation during mitosis and meiosis. Aurora A appears to control premetaphase events, such as bipolar spindle assembly 3, 4, with Aurora B and C directing metaphase and postmetaphase events, including

• br Structure of V ATPase V ATPase is a highly

  2023-12-19

  

  Structure of V-ATPase V-ATPase is a highly conserved multi-subunit enzyme that uses energy from ATP hydrolysis to transport protons across membranes [2], [3], [4]. It consists of two major functional domains, V1 and V0 (Fig. 1). The former has eight different subunits (A, B, C, D, E, F, G, and H)

• We used the lead compound C

  2023-12-19

  

  We used the lead compound C4 to demonstrate that small molecule ACL inhibitors can recapitulate ACL knockdown (KD) in modulation of cancer stemness. We have shown previously that ACL KD reduced the CSC population in multiple cancer cell lines. The E-snail cells are an established CSC model system.

• ATM is required for the proper function of

  2023-12-19

  

  ATM is required for the proper function of the DNA-repair pathway in response to bleomycin-induced DNA damage in mammalian cells [55], [56]. Recent reports suggest that ATM activation by double-strand breaks leads to the subsequent ATR activation [57], [58], [59]. The recruitment of ATR to double-st

• TLRs play a key role in pathogen recognition

  2023-12-19

  

  TLRs play a key role in pathogen recognition and early response. In our study, we showed an increase of TLR2 mRNA and protein expression after BMECs were stimulated by S. aureus, as seen for BMECs in a previous study [25]. Although most studies describe TLR4 as a primary receptor for Gram-negative b

• Most human diseases e g cancer diabetes and

  2023-12-19

  

  Most human diseases (e.g., cancer, diabetes, and neurodegenerative diseases) are complex and multifactorial. Several investigations in the literature focused on new multi-target drug development, which implies active pharmacophores incorporation in one scaffold (Meunier, 2008, Lazar et al., 2004, Te

• Thiol are reduced by two major redox systems glutathione

  2023-12-19

  

  Thiol are reduced by two major redox systems, glutathione/glutaredoxin (GRX) and thioredoxin (TRX), which have been extensively studied in plants [13], [14], [15]. Glutathione, a thiol-containing tripeptide, exists in a reduced (GSH) or an oxidized form (GSSG). It has a major role as a redox buffer.

• What are the in situ effects of multi site CaM

  2023-12-19

  

  What are the in-situ effects of multi-site CaM associations with AT1R? Kai et al. showed that synthetic peptides corresponding to residues 125–137 (rat sequence) in SMD2, 217–227 in the N-terminal side of SMD3, and 304–316 in SMD4JM inhibit to various degrees AngII-induced GTPase activity of isolate

• In receptor binding terminology both

  2023-12-19

  

  In receptor binding terminology, both receptor and acceptor contain a receptive site for the ligand, although only the receptor induces a biological function. Moreover, the acceptor lacks an endogenous ligand. Many proteins have been described as receptors for toxic Aβ assemblies, implying a designe

• Lorlatinib is an orally active brain penetrant cyclic

  2023-12-19

  

  Lorlatinib is an orally active brain penetrant cyclic 2-aminopyridine derivative that is a type I½ B ALK inhibitor (Fig. 5F) [61]. This medicinal is an effective antagonist against the more common L1196M and G1269A crizotinib-resistant mutations as well as the less common T1151Ins, L1152R, C1156Y, F

• Targeted disruption of the Akt

  2023-12-19

  

  Targeted disruption of the Akt1 gene in mice induces a growth retardation phenotype [4,19]. Akt2 KO mice reveal mild growth retardation and insulin resistance [4,20,21]. Akt1/2 double KO (DKO) mice display severe growth deficiency and die shortly after birth. These mice exhibit impaired bone and ski

14880 records 221/992 page Previous Next First page 上5页 221222223224225 下5页 Last page